EGFR and urinary bladder carcinoma: In the current study, we demonstrate that cisplatin treatment induces EGFR activation in bladder cancer cells, resulting in the upregulation of the ProT-NF-κB-HOTAIR axis and leading to promoting cachexia-associated pro-inflammatory cytokine expression.